Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
Recent  |  14: Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
04/10/2014 > 139 patent applications in 109 patent subcategories.

20140100154 - Prodrugs of peptide epoxy ketone protease inhibitors: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.... Agent: Onyx Therapeutics, Inc.

20140100155 - Combination therapy and kit for the prevention and treatment of cystic fibrosis: A combination therapy and kit including an agent that inhibit the interaction between CAL and mutant CFTR proteins, in combination with a CFTR corrector, CFTR potentiator, mucolytic, anti-inflammatory agent or a combination thereof are provided as is a method for preventing or treating cystic fibrosis.... Agent: Trustees Of Dartmouth College

20140100156 - Exendin-4 derivatives as dual glp1/glucagon agonists: The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.... Agent: Sanofi

20140100157 - Method of inhibiting clostridium difficile by administration of oritavancin: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against both a vegetative form of C. difficile and C. difficile spores. Methods for the treatment, prophylaxis and prevention of C. difficile infection and disease in animals, including humans, are described.... Agent: The Medicines Company

20140100158 - Use of ultrarapid acting insulin: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.... Agent: Mannkind Corporation

20140100160 - Novel use of c-terminal domain of igfbp-5 comprising heparin-binding domain as an angiogenesis inhibitor: The present invention relates to a pharmaceutical composition for inhibiting angiogenesis comprising an isolated peptide comprising the heparin-binding domain of insulin-like growth factor-binding protein-5 (IGFBP-5), a method for inhibiting angiogenesis using the peptide, a pharmaceutical composition for the prevention or treatment of cancer comprising the peptide, a method for treating... Agent: Research & Business Foundation Sungkyunkwan University

20140100159 - Use of relaxin to restore maternal physiology in pregnancies conveived by assisted reproductive technologies: The subject invention relates to methods for improving a subject's vasculature to normalize maternal hemodynamics, particularly in subjects attempting to conceive via assisted reproductive technologies, and comprises increasing relaxin levels in a subject or increasing any one or more of: relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin... Agent: University Of Florida Research Foundation, Inc.

20140100161 - System and method for multiphasic release of growth factors: A system for multiphasic delivery of at least one growth factor at a treatment site comprises a delivery vehicle for releasing at least one growth factor in an initial release profile and a carrier for releasing at least one growth factor in a sustained release profile. The initial release profile... Agent: Induce Biologics Inc.

20140100162 - Prevention of kidney injury disease: The present invention relates to a dosage regime of a peptide analogues of [alpha]-melanocyte-stimulating hormone ([alpha]-MSH), which possesses an increased efficacy compared to the native [alpha]-MSH peptide in the treatment or prevention of kidney injury or disease.... Agent: Abbvie, Inc.

20140100163 - Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide: This invention relates, e.g., to methods for inhibiting or stimulating an activity of an adrenomedullin (AM) or gastrin releasing peptide (GRP) peptide hormone, comprising contacting the peptide with a small molecule, non-peptide, modulatory agent of the invention. Complexes of these modulatory agents with other components, such as the peptides or... Agent: The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

20140100164 - Peptide modulators of angiogenesis and use thereof: The invention generally features compositions and methods that are useful for modulating blood vessel formation, as well as methods that provide for the systematic and efficient identification of angiogenesis modulators. As described in more detail below, a systematic computational methodology based on bioinformatics was used to identify novel peptide modulators... Agent: The Johns Hopkins University

20140100165 - Prevention of kidney injury or disease: The present invention relates to a dosage regime of a peptide analogues of [alpha]-melanocyte-stimulating hormone ([alpha]-MSH), which possesses an increased efficacy compared to the native [alpha]-MSH peptide in the treatment or prevention of kidney injury or disease.... Agent:

20140100166 - Methods for the prevention or treatment of heart failure: The disclosure provides methods of preventing or treating heart failure in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof.... Agent: Cornell University

20140100167 - Assessment of cardiac health and thrombotic risk in a patient: The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk... Agent:

20140100168 - Prodrugs of peptide epoxy ketone protease inhibitors: This disclosure features compounds that are useful as pro-drugs of epoxy ketone protease inhibitors.... Agent:

20140100169 - Compounds for enzyme inhibition: One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering... Agent: Onyx Therapeutics, Inc.

20140100171 - Methods of improving the appearance of aging skin: A method of improving the appearance of aging skin includes applying to skin tissue having dullness or lack of radiance, or eleven lines, marionette lines, or horizontal forehead lines, or sagging skin, a composition containing S-acyl glutathione derivative having unsaturated or saturated C16 acyl group.... Agent:

20140100170 - Plant-derived elastin binding protein ligands and methods of using the same: The present invention describes novel plant derived elastin-like peptides and peptidomimetics that may serve as functional ligands for elastin receptors and stimulate elastogenesis. The novel plant derived peptides provide an alternative (non-animal derived) source of GXXPG (SEQ ID NO. 2) containing peptides. The present invention also describes therapeutic compositions containing... Agent: Human Matrix Sciences, LLC

20140100172 - Cancer imaging and treatment: Provided herein are compounds useful for diagnostic imaging and/or therapeutic purposes. Each compound comprises a ligand for the chemokine receptor CXCR4, which has a binding affinity for the CXCR4 receptor, measured as IC50 in the presence of 125I-CPCR4, of 250 nM or lower. The ligand is a cyclic oligopeptide moiety... Agent: Mallinckrodt LLC

20140100173 - Nitrile-containing enzyme inhibitors and ruthenium complexes thereof: The invention provides nitrile-containing protease inhibitors caged to ruthenium compounds. The nitrile-caged ruthenium compounds provide inactivated inhibitors that can be delivered to surface or site for activation, for example, but exposure to light. The invention also provides methods for delivering protease inhibitors to subjects for the therapeutic treatment of conditions... Agent: Wayne State University

20140100175 - Insecticidal agents and uses thereof: The present invention provides insecticidal lipids and lipid fractions from fungi of the phylum Ascomycota, together with compositions comprising such lipids and lipid fractions and methods of preparing same. Methods for the biological control of insects, such as phytopathogenic insects, using the lipids and lipid fractions or compositions comprising said... Agent: Biotelliga Holdings Limited

20140100176 - L-sugar colon cleansing agent and uses thereof: Disclosed is L-glucose monohydrate and compositions thereof. Also disclosed are methods for making L-glucose monohydrate and compositions thereof. Further disclosed are methods for colonic cleansing using L-sugars, such as L-glucose monohydrate, and compositions and kits useful for colonic cleansing.... Agent: Aptalis Pharma Us, Inc.

20140100174 - Treatment for cancer: s

20140100177 - Composition comprising cashew apple extract: The invention concerns a cashew apple extract and a composition comprising a cashew apple extract and optionally a carrier, in particular for use for allowing reduction of body weight gain or limitation of increasing body weight, reduction or limitation of fat storage, of fatty liver, of liver triglycerides level, of... Agent: Dialpha

20140100178 - Composition and methods for site-specific drug delivery to treat malaria and other liver diseases: A system for selectively delivering drugs to target tissues is provided. The system includes a drug-linker-saccharide-drug conjugate (D-L-A-D1). The linker includes a functional group that is recognized and cleaved by enzyme in the target phases. The recognition segment is preferably a malaria drugs. The carrier is preferably hydrophilic, biodegradable and... Agent:

20140100179 - Novel urea compounds: s

20140100180 - Topical pharmaceutical composition based on semifluorinated alkanes: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and... Agent: Novaliq Gmbh

20140100181 - Topical pharmaceutical composition containing a water-sensitive active principle: A topical pharmaceutical composition including, as a pharmaceutical active agent, a water-sensitive compound in a solubilised form in a physiologically acceptable medium is described. A method for preparing such a composition, and uses thereof in dermatology are also described.... Agent: Galderma S.a.

20140100182 - Nanogel-mediated drug delivery: Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated... Agent: The Cleveland Clinic Foundation

20140100262 - Methods and compositions for maintaining blood-brain barrier integrity: Methods of maintaining or improving blood-brain barrier integrity and increasing resistance to cytokine-induced cell permeability are disclosed. It has been discovered that down-regulating the expression or production of sulfoglucuronyl glycolipids, for example SGPG, in endothelial cells of the blood-brain barrier or the blood-nerve barrier reduces apoptosis of these endothelial cells... Agent: Georgia Regents Research Institute, Inc.

20140100263 - Methods for treatment of alport syndrome: Provided herein are methods for the treatment of Alport Syndrome, using modified oligonucleotides targeted to miR-21. In certain embodiments, a modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport Syndrome. In certain embodiments, administration of a modified oligonucleotide targeted to miR-21 delays the onset... Agent: Regulus Therapeutics Inc.

20140100264 - Methods of treatment relating to the fmr1 gene: A method of treating a human female to increase embryo survival and embryo quality includes administering an FMR1 enhancer to a human embryo to cause an increase in expression of an FMR1 gene. The FMR1 enhancer increases the expression of FMR1 genes in the human embryo with at least one... Agent:

20140100261 - Trpm-2 antisense therapy: A method for treating an individual suffering from a cancer comprising administering to the individual a chemotherapeutic agent, and ii) one antisense oligonucleotide having nucleotides in the sequence set forth in Seq. ID No. 4 and which antisense oligonucleotide has a phosphorothioate modification that increases the stability thereof in vivo,... Agent: The University Of British Columbia

20140100266 - Cancer treatment by combining dna molecules mimicking double strand breaks with hyperthermia: The present invention relates to a method for treating a cancer including a combination of a treatment by a nucleic acid molecule mimicking double strand breaks with hyperthermia.... Agent: Institut Curie

20140100265 - Gene delivery vehicles in the treatment of neurodegenerative diseases: Currently no therapies that provide either protection or restoration of neuronal function for adult onset neurodegenerative diseases such as Parkinson's disease exist. Many clinical efforts to provide such benefits by infusion of neurotropic factors have failed. An alternative approach such as viral construct transduction may be used to directly activate... Agent: The Trustees Of Columbia University In The City Of New York

20140100183 - Central administration of stable formulations of therapeutic agents for cns conditions: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing... Agent: The Regents Of The University Of Colorado, A Body Corporate

20140100184 - Selective inhibitors of histone methyltransferase dot1l: Structure and mechanism based design was used to design potent ribose containing inhibitors of DOT1L with IC50 values as low as 38 nM. These ribose containing inhibitors exhibit only weak or no activities against four other representative histone lysine and arginine methyltransferases, G9a, SUV39H1, PRMT1 and CARM1.... Agent: Baylor College Of Medicine

20140100185 - Unit dosage of apadenoson: The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging.... Agent: University Of Virginia Patent Foundation

20140100186 - Method to improve antiviral activity of nucleotide analogue drugs: A method of modifying a nucleotide or a nucleotide analogue to increase its overall effectiveness in treating an antiviral disease is provided. In some cases, a compound comprising a base, sugar, phosphonate moiety, and amino acid residue is provided, where the base-sugar may be a nucleoside, and the amino acid... Agent:

20140100187 - Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine: A first aspect of the invention relates to a combination comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof. A second aspect of the invention relates to a pharmaceutical product comprising a DNA methyltransferase inhibitor and 1-(2-C-cyano-2-dioxy-β-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, or a metabolite thereof, as a combined preparation for... Agent: Cyclacel Limited

20140100188 - Phenotyping tumor-infiltrating leukocytes: The present disclosure relates to an immune signature of tumor infiltrating leukocytes. In particular, the disclosure provides methods and kits for determining the immune signature of tumor infiltrating leukocytes for use in assessing risk of cancer recurrence and long term survival, and for developing a treatment regimen for a cancer... Agent: The Regents Of The University Of California

20140100189 - Carbohydrates mixture: A carbohydrate mixture for dietetic foods and pharmaceuticals is provided. The carbohydrate mixture comprises two different, substantially soluble carbohydrate components A and B, which remain undigested in the gastrointestinal tract and enter the large intestine without being resorbed. Carbohydrate component A may comprise at least one monosaccharide or of at... Agent: N.v. Nutricia

20140100190 - Use of lipid conjugates in cystic fibrosis and applications thereof: wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd

20140100192 - Pharmaceutical formulation containing choline alfoscerate: The present invention provides choline alfoscerate-containing pharmaceutical preparations which have improved storage-stability and are easily taken. The present invention also provides a method for manufacturing pharmaceutical preparations comprising choline alfoscerate, which is easy and simple and is performed by normal manufacturing equipments.... Agent: Ctc Bio, Inc.

20140100191 - Vesicular formulations: Disclosed herein are vesicular formulations that include one or more phospholipids and one or more surfactants and in certain embodiments the use of such formulations for the delivery of fatty acids for the treatment of disorders such as, fatty acid metabolic disorders, including essential fatty acid deficiency; pain or inflammation... Agent:

20140100194 - Cold menthol receptor-1 antagonists: The invention is directed to TRPM8 antagonists of Formula (I). More specifically, the present invention relates to certain novel compounds, methods for preparing compounds, compositions, intermediates and derivatives thereof and methods for treating TRPM8-mediated disorders. Pharmaceutical and veterinary compositions and methods of treating pain and various other disease states or... Agent: Janssen Pharmaceutica, Nv

20140100193 - Diazonamide analogs: Diazonamide analogs having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders, and related pharmaceutical compositions are provided.... Agent: Joyant Pharmaceuticals, Inc.

20140100195 - Heterobicyclic sphingosine 1-phosphate analogs: Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.... Agent:

20140100197 - Bicyclic 1, 2, 4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators: The present invention relates to bicyclic aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20140100198 - Enzyme inhibiting compounds and methods: The invention provides compounds, compositions, and methods for studying the Rohmer pathway and for treating bacterial infections or parasitic infections. The parasitic infection can be a protozoan infection, such as malaria. The compounds and compositions can also be used as antibiotics, for example, to kill bacteria or parasites, or to... Agent: The Board Of Trustees Of The University Of Illinois

20140100196 - Phytosanitary microemulsion and the procedure for obtaining it: A phytosanitary microemulsion and procedure for obtaining it, wherein the resulting microemulsion is highly stable, with low content of surfactants, achieved due to a combination of an active ingredient, preferably cypermethrin, chlorpirifos or mixtures thereof; refined soy oil; a surfactant at a very low content due to the inclusion of... Agent: Red Surcos S.a.

20140100199 - Substituted aryl 1 ,2,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators: The present invention relates to substituted aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20140100200 - Methods of treating acne: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.... Agent: Galderma Laboratories, Inc.

20140100201 - Connective tissue monitoring, compositions for connective tissue treatment and methods for treating connective tissue: Methods and computer instruction code for monitoring, screening and classifying the response to load of a connective tissue or part thereof are disclosed. The method includes the steps of obtaining or receiving an ultrasound scan of a connective tissue or part thereof and analysing the ultrasound scan to detect one... Agent: Trackside Technologies Pty Ltd.

20140100202 - Process for the preparation of a metal complex in an oily organic matrix: A process is described for the preparation of a composition comprising a metal complex in an oily organic matrix, the latter being at the same time able to promote the formation of the complex. Said process also envisages that the complex, once formed, is not separated from said oily organic... Agent: Volare & Connecting, LLC

20140100203 - Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration: An oral dosage form comprising a single dose of 25-hydroxy-vitamin D3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and a pharmaceutically suitable oral carrier system, wherein subsequent single doses at least... Agent: Wisconsin Alumni Research Foundation

20140100204 - Natural combination hormone replacement formulations and therapies: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with... Agent: Therapeuticsmd, Inc.

20140100205 - Natural combination hormone replacement formulations and therapies: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with... Agent: Therapeuticsmd, Inc.

20140100206 - Natural combination hormone replacement formulations and therapies: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with... Agent: Therapeuticsmd, Inc.

20140100207 - Use of 19 nor dhea derivatives for enhancing physical performance: A method is disclosed for administering a DHEA derivative or a physiologically acceptable salt, ester or ether thereof for one of decreasing body weight, reducing adipose tissue, increasing endurance, as an anti-aging compound and generating production of red blood cells.... Agent: Intellectual Wellness, LLC

20140100208 - Progesterone antagonist and selective progesterone modulator in the treatment of excessive uterine bleeding: Progesterone antagonists and SPRM are useful to prepare a medication for the treatment or the prophylaxis of excessive uterine bleeding in women with spontaneous or iatrogenic coagulation disorders such as thrombopenia, coagulation factor deficiency or anti-coagulant therapy. Treatment will last from 1 day to 180 days.... Agent: Preglem S.a.

20140100209 - Tgr5 modulators and methods of use thereof: o

20140100212 - Compounds as tyrosine kinase modulators: The present invention is directed to novel compounds of Formula I. The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.... Agent: Allergan, Inc.

20140100214 - Heterocyclic compounds and uses thereof: Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including P13 kinase activity, are described herein.... Agent: Infinity Pharmaceuticals, Inc.

20140100215 - Methods of using pi3k and mek modulators: The invention provides methods of treating cancer with a combination of compounds which inhibit kinases, more specifically MEK and PI3K.... Agent: Exelixis, Inc.

20140100211 - New pyrrolidine derivatives, pharmaceutical compositions and uses thereof: e

20140100213 - Triazolones as fatty acid synthase inhibitors: This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.... Agent: Glaxosmithkline LLC

20140100210 - Guanidine compound: The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that the compound or a salt thereof of the present invention exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular,... Agent: Astellas Pharma Inc.

20140100216 - Stimulators of incretin hormones secretion, method for preparation and use thereof: The invention relates to the area of medicinal chemistry, pharmacology and medicine and includes description of pharmaceutical compositions and combined medicaments on the base of secretion stimulators and protectors of incretin hormones for treatment of metabolic diseases (among them, diabetes, obesity, metabolic syndrome and the like). The invention consists in... Agent:

20140100217 - Structural mimetics of proline-rich peptides and their use: In general formula 1, X is at least one of O and S. A is a ring bridge. Y1 is at least one of H, alkyl, fluoroalkyl, aryl and heteroaryl. Z1, Z2, Z3 are, individually or alternatively, at least one of H, carbonyl, OH, O-alkyl, O-acyl, N—R1R2 (where R1 or... Agent: Universitaet Zu Koeln

20140100218 - Treatment of mild and moderate alzheimer's disease: The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4-yl}-phenoxy)-propyl]-diethyl amine (“COMPOUND I”) or a pharmaceutically acceptable salt thereof. In various embodiments, the methods of treatment include treatment of mild-to-moderate dementia of Alzheimer's type, diabetes, insomnia, and other indications. The present invention also relates to pharmaceutical compositions comprising COMPOUND I... Agent: Transtech Pharma, LLC

20140100219 - Modified release preparations containing oxcarbazepine and derivatives thereof: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.... Agent: Supernus Pharmaceuticals, Inc.

20140100220 - Novel compound useful for the treatment of degenerative and inflammatory diseases: A novel compound able to inhibit JAK is disclosed, this compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection,... Agent: Galapagos Nv

20140100221 - 1h-pyrrolo[2,3-b]pyridine derivatives: 1H-Pyrrolo[2,3-b]pyridine compounds are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.... Agent: Merck Patent Gmbh

20140100222 - Beta2-adrenoceptor agonist for the treatment of cough: -

20140100223 - Compounds and methods for the treatment of isocitrate dehydrogenase related diseases: The invention relates to compounds of Formula I or a pharmaceutically acceptable salt, ester or prodrug thereof:... Agent: The Broad Institute, Inc.

20140100224 - Neurotrophin mimetics and uses thereof: The present application is related to compounds which are novel neurotrophin mimetics. The application also discloses the treatment of disorders associated with p75 expression, such as degradation or dysfunction of cells expressing p75 in a mammal by administering an effective amount of such compounds.... Agent: The Regents Of The University Of California

20140100225 - Novel compounds, their preparation and their uses: Novel compounds and their synthesis are described. Methods for using these compounds in the prevention or treatment of cancer, a bacterial infection or a viral infection in a subject are also described.... Agent: Sphaera Pharma Pte. Ltd.

20140100226 - Oxazole compound and pharmaceutical composition: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(═O)— wherein Y1 is a group such... Agent: Otsuka Pharmaceutical Co., Ltd.

20140100227 - C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof: e

20140100229 - Fluoroalkyl-substituted pyrazolopyridines and use thereof: The present application relates to novel fluoroalkyl-substituted pyrazolopyridines, to processes for their preparation, to their use, alone or in combinations, for the treatment and/or prophylaxis of diseases and to their use for production of medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prophylaxis of cardiovascular... Agent: Bayer Intellectual Property Gmbh

20140100228 - Small molecule inhibitors of influenza a rna-dependent rna polymerase: Antiviral compositions and methods are contemplated that are especially effective in the treatment and prevention of influenza A viruses. Also presented are cellular assays to identify small molecule compounds having antiviral properties, particularly as it relates to detection of influenza A RNA-dependent RNA polymerase activity in a mammalian cell independent... Agent: Nant Holdings Ip, LLC

20140100230 - Methods and compositions for treating anxiety: Methods of treating a TRPC5 mediated disorder in a subject by administering an effective amount of a TRPC5 antagonist, such as a compound disclosed herein, are described.... Agent: Hydra Biosciences, Inc.

20140100231 - Non-nucleoside reverse transcriptase inhibitors: are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the... Agent:

20140100232 - Combination treatment for rosacea: The invention relates to a method of treating erythema and/or telangiectasia associated with rosacea in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the site of erythema... Agent: Galderma Laboratories Inc.

20140100233 - Crystalization of pharmaceutical compounds: Novel crystalline forms of tadalafil suitable for pharmaceutical compositions in drug delivery systems for humans.... Agent: Thar Pharmaceuticals, Inc.

20140100234 - Quinoline derivatives as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Glaxosmithkline LLC

20140100235 - Pyrazinone derivatives as insulin secreton stimulators, methods for obtaining them and use thereof for the treatment of diabetes: The present invention relates to pyrazinone derivatives of formula (I), wherein n, R1, R2, R3 and R4 are as defined in claim 1, as insulin secretion stimulators. The invention also relates to the preparation and use of these pyrazinone derivatives for the prophylaxis and/or treatment of diabetes and pathologies associated.... Agent: Merck Patent Gmbh

20140100236 - Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginin: The present invention relates inter alia to the use of selectively moisture-adjusted tabletting material in the preparation of mechanically stable oral tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing oral tablets.... Agent: Boehringer Ingelheim International Gmbh

20140100237 - Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation: Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.... Agent: Chemocentryx, Inc.

20140100238 - Method of diagnosing and treating epstein barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients: A method of diagnosing a subset of Epstein Barr Virus, Myalgic Encephalomyelitis Chronic Fatigue Syndrome (ME/CFS) patients through a multi-prong clinical/serological analysis is provided wherein Epstein Barr Virus Abortive Lytic Replication (EBV) is determined as the specific causal agent through the use of serum antibodies to EBV encoded dUTPase and... Agent: Cfs, LLC

20140100239 - Quinazolinedione derivatives as parp inhibitors: m

20140100241 - Drug detoxification protocol using microdosing: This invention relates to use of an opioid receptor agonist in microdose quantities to reduce or eliminate the withdrawal symptoms associated with discontinuing drug use. The dosage of the agonist is reduced over an extended period of time.... Agent:

20140100240 - Natural product derivatives with antiprotozoal activity: The present invention provides new chemical compositions with desirable biological activity and toxicity profiles for the enhanced treatment of malaria.... Agent: Radix Pharmaceuticals, Inc.

20140100242 - Inhibition of quorum sensing-mediated processes in bacteria: Methods are provided for identifying molecules that can be used to positively and negatively manipulate quorum-sensing-mediated communication to control bacterial behavior. Small-molecule antagonists that disrupt quorum-sensing-mediated activities are identified. Methods are provided for disrupting detection of acyl-homoserine lactone autoinducer in Gram-negative bacteria by contacting the bacteria with the antagonists. Methods... Agent: The Trustees Of Princeton University

20140100243 - Substituted 4-aryl-1,4-dihydro-1,6-naphthyridine amides and their use: The present application relates to novel substituted 4-aryl-1,4-dihydro-1,6-naphthyridine-3-carboxamides, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.... Agent: Bayer Intellectual Property Gmbh

20140100244 - Preventive and/or therapeutic agent for thromboembolism in thromboembolism patient with severe renal impairment: It is intended to provide a highly safe, orally administrable preventive and/or therapeutic agent for thrombosis and/or embolism that can be applied to a thrombosis and/or embolism patient with severe renal impairment. The present inventors have found that even for a thrombosis and/or embolism patient with severe renal impairment, use... Agent: Daiichi Sankyo Company, Limited

20140100245 - Antiviral drugs for treatment of arenvirus infection: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by... Agent: Siga Technologies, Inc.

20140100246 - Aclidinium for use in improving the quality of sleep in respiratory patents: The present invention provides aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for improving the quality of sleep in respiratory patients.... Agent:

20140100247 - Method of treating apraxia of speech in children: A therapeutic method for treating apraxia of speech in children. The child can also be diagnosed with autism, mental retardation, dyslexia. Verbal development stages and nonverbal development stages are tested and observed. If a child demonstrates at least 18 to 24 month development stage of either the verbal development or... Agent:

20140100248 - Novel heterocyclic compounds as modulators of sphingolipid signaling and uses thereof: The present invention relates to new heterocyclic compounds as modulators of sphingolipid signaling and uses thereof of as pharmaceutically active agents, suitable for treating proliferative, degenerative, infectious, and other diseases.... Agent: Johann Wolfgang Goethe-universit&#xc4 T

20140100249 - Therapeutic treatment: This invention discloses a treatment for a patient receiving medication to treat an attention deficit disorder such as ADHD wherein the treatment results in a loss of appetite and impairment of the patient's attentiveness. The treatment combines a treatment for an attention deficit disorder with an appetite stimulant, wherein the... Agent:

20140100250 - Pyridyl aminopyridines as syk inhibitors: The present invention provides novel pyrimidine amines of formula I which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.... Agent:

20140100251 - 1, 2, 4-oxadiazoles azetidine derivatives as sphingosine-1 phosphate receptors modulators: The present invention relates to 1,2,4-oxadiazoles azetidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.... Agent: Alergan, Inc.

20140100252 - Amorphous ritonavir co-precipitated: The present invention relates to amorphous ritonavir co-precipitated on copovidone, process for its preparation and pharmaceutical compositions comprising it.... Agent:

20140100253 - Synergistic antimicrobial composition of 1,2-benzisothiazolin-3-one and tris(hydroxymethyl)nitromethane: A synergistic antimicrobial composition containing 1,2-benzisothiazolin-3-one and tris(hydroxymethyl)nitromethane.... Agent:

20140100254 - Radezolid salts and polymorphic forms thereof: s

20140100255 - Novel compounds as antagonists or inverse agonists at opioid receptors: Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.... Agent: Glaxosmithkline LLC

20140100256 - Formulations of enzalutamide: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.... Agent: Medivation Prostate Therapeutics, Inc.

20140100257 - Treatment or prevention of hypotension and shock: The present invention relates to a method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof. In addition, the present invention relates... Agent: Orion Corporation

20140100258 - Methods for treating degenerative diseases/injuries: Invented is a method of treating cardiovascular disease/injury, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.... Agent: Glaxosmithkline LLC

20140100259 - Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof: Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-α or the inhibition of PDE4.... Agent: Celgene Corporation

20140100260 - Enalapril compositions: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.... Agent:

20140100267 - Functional food additives: Novel compounds, and in particular to diacylglycerol (1, 3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress... Agent:

20140100268 - Oligomer-tricyclic conjugates: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble... Agent: Nektar Therapeutics

20140100269 - Oral cannabinoid formulations: Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.... Agent: Insys Therapeutics, Inc.

20140100270 - Radiation countermeasure agents: Methods and compositions for reducing radiation damage in a subject with analog or derivative of benzo[c]chromen-6-one.... Agent:

20140100271 - New 5-aminolevulinic acid prodrugs for use in photodynamic therapy and photodynamic diagnosis: and salts thereof, where R1 is an oxime or an alkylated oxime; the alkylated oxime comprises a linear or branched alkyl group of length C1 to C5; and R2 are each independently (a) an unsubstituted or substituted linear or branched alkyl group of chain length C1-7, (b) an aryl substituted... Agent: Swedish Pharma Ab C/o Inkubera Ab

20140100272 - Methods of administering compositions comprising docosapentaenoic acid: The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.... Agent: Matinas Biopharma, Inc.

20140100273 - Methods of administering compositions comprising docosapentaenoic acid: The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.... Agent: Matinas Biopharma, Inc.

20140100274 - Methods of administering compositions comprising docosapentaenoic acid: The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.... Agent: Matinas Biopharma, Inc.

20140100275 - Methods of administering compositions comprising docosapentaenoic acid: The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.... Agent: Matinas Biopharma, Inc.

20140100276 - Emulsified composition: e

20140100278 - Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event: The present invention relates to compounds according to formula (I) for medical use. The compounds are particularly suitable for the treatment and/or prevention of a medical condition involving hypoxic, anoxic and/or inflamed mammalian tissue. Furthermore, the invention relates to the use of said compounds for preparing a medicament and to... Agent: University Of Zurich

20140100277 - Solutions and methods of making solutions to kill or deactivate spores, microorganisms, bacteria and fungus: Exemplary embodiments of solutions of plasma activated water and peroxyacetic acid are disclosed herein. In addition, exemplary embodiments of methods for making solutions are disclosed herein. Some methods include exposing water to a plasma gas to activate the water, adding acetic acid to the activated water; and mixing the acetic... Agent: Ep Technologies LLC

20140100279 - Extracts from eucalyptus camaldulensis for the treatment of hyperglycemia and hypertension: The present invention relates to the discovery that compounds isolated from the leaves of the plant Eucalyptus camaldulensis can be used to treat or prevent hyperglycemia and/or hypertension.... Agent: The University Of The West Indies

20140100281 - Omega-3 pentaenoic acid compositions and methods of use: Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA)... Agent: Matinas Biopharma, Inc.

20140100280 - Treatment methods using very long chain polyunsaturated fatty acids: Compositions that include Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs) are disclosed, along with methods of production and use thereof.... Agent: The Board Regents Of The University Of Oklahoma

20140100282 - Intranasal administration of pharmaceutical agents for treatment of neurological diseases: Pharmaceutical formulations for treating neurological diseases are described, wherein the formulations comprise a pharmaceutically active agent-transport moiety complex. The formulations are suitable for administration via an intranasal route. Neurological diseases and conditions are associated with reduced brain insulin signaling (i.e., CNS insulin insensitivity), reduced dopaminergic signaling, reduced serotonergic signaling, reduced... Agent:

20140100283 - Method to increase absorption and bioavailability of oral glutathione: An improved method for delivery of glutathione, a major intracellular antioxidant, by oral administration of S-acetyl-glutathione (SAG) is provided. The method is designed to raise the circulating blood levels of glutathione via the administration of an effective amount of SAG in a delayed release composition.... Agent: Atlantic Pro Nutrients, Inc. Dba Xymogen

20140100284 - Rapid-acting, blood-arginine-level-increasable oral preparation comprising citrulline and arginine: The present invention provides a rapid-acting, blood arginine level-increasing oral preparation containing citrulline or a salt thereof and arginine or a salt thereof as active ingredients. The rapid-acting, blood arginine level-increasing oral preparation of the present invention can rapidly and effectively increase blood arginine level after ingestion, and can rapidly... Agent: Kyowa Hakko Bio Co., Ltd.

20140100285 - Compositions of percutaneous administration of physiologically active agents: Compositions intended for the percutaneous administration of physiologically active agents, e.g. drugs or a veterinary agents, are disclosed. Said compositions are characterized forming a non-sticky, very flexible film that ‘has excellent long term efficacy.... Agent: Novartis Ag

20140100286 - Composition for preventing or treating inflammatory diseases comprising veratric acid as effective component: There is provided a composition including a veratric acid for preventing or treating inflammatory diseases. The veratric acid of the present invention has an excellent effect of inhibiting production of nitric oxide, an excellent activity of inhibiting production of IL-1β as a pro-inflammatory cytokine, and an excellent effect of inhibiting... Agent:

20140100287 - Enhanced bimatoprost ophthalmic solution: e

20140100288 - Foaming topical antimicrobial cleaning compositions: Provided are largely aqueous topical antimicrobial cleaning composition which provides an antimicrobial benefit, as well as methods for their production and methods for their use. The compositions comprise at least two different cationic surfactants which provide a primary antimicrobial benefit, and as a predominant further surfactant an amine oxide surfactant.... Agent: Reckitt & Colman (overseas) Limited

20140100289 - Methods and compositions for treating mammalian nerve tissue injuries: To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be performed by directly contacting the agent with the nerve tissue at the site of the... Agent:

20140100290 - Method of treating a prostate condition: A method of treating a prostate cancer condition in a mammal in need of such treatment is disclosed. The method comprises administrating to the mammal an anti-prostate cancer effective amount of a compound of a plant essential oil.... Agent:

20140100291 - Actinically-crosslinkable siloxane-containing copolymers: The invention provide a class of actinically-crosslinkable silicone-containing prepolymers obtained by functionalizing an intermediary copolymer to have two or more thiol or ethylenically-unsaturated groups covalently attached thereto, wherein the intermediary copolymer is an atom-transfer radical polymerization (ATRP) product of a reactive mixture comprising a polysiloxane ATRP macroinitiator and at least... Agent: Novartis Ag

20140100292 - Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets: The present invention relates inter alia to the use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolution kinetics (dissolution) and/or the water loading of tablets.... Agent: Boehringer Ingelheim International Gmbh

  
04/03/2014 > 131 patent applications in 100 patent subcategories.

20140094399 - Biodegradable poly(beta-amino esters) and uses thereof: Poly(β-amino esters) prepared from the conjugate addition of bis(secondary amines) or primary amines to a bis(acrylate ester) are described. Methods of preparing these polymers from commercially available starting materials are also provided. These tertiary amine-containing polymers are preferably biodegradable and biocompatible and may be used in a variety of drug... Agent: Massachusetts Institute Of Technology

20140094400 - Novel angiotensin type 2 (at2) receptor agonists and uses thereof: The invention relates to novel pharmaceutically-useful peptides, in particular cyclic peptides that are agonists of the AngII type 2 receptor (AT2 receptor). The invention further relates to the use of such peptides as medicaments, to pharmaceutical compositions containing them, and to their production.... Agent: Lanthiopep B.v.

20140094401 - Mitrecin a polypeptide with antimicrobial activity: The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be... Agent: The Mitre Corporation

20140094403 - Enopeptins, uses thereof, and methods of synthesis thereto: Provided herein are inventive enopeptin compounds of Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Further provided are methods of preparation, use, and treatment.... Agent: Brown University

20140094402 - Lantibiotic nai-802, pharmaceutically acceptable salts, compositions and uses thereof: The present invention concerns novel lantibiotic compounds, processes for the isolation and preparation thereof, pharmaceutical compositions containing the same, pharmaceutical acceptable salts thereof, and methods of use of the lantibiotics as antibacterial agents.... Agent: Sentinella Pharmaceuticals, Inc.

20140094405 - Cholesterol derivatives of inhibitors of viral fusion: The present invention relates to compounds comprising at least ten contiguous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit... Agent: Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.r.l.

20140094404 - Methods and reagents for efficient and targeted delivery of therapeutic molecules to cxcr4 cells: The invention relates to conjugates comprising a targeting moiety specific for the CXCR4 based on the polyphemusin-derived peptide and a therapeutic or imaging agent. The invention relates as well to the application of said conjugates for the therapy and diagnostics which require the specific targeting to CXCR4+ cells.... Agent:

20140094406 - Chimeric fibroblast growth factor 21 proteins and methods of use: The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF21 molecule. The portion of the paracrine FGF is modified to decrease... Agent: New York University

20140094407 - Devices and methods for treating and/or preventing diseases: The invention relates to a therapeutic device for the delivery of therapeutic agents, e.g. a peptide such as leuprolide, via the vagina to a female mammal. In some embodiments, the invention also relates to methods for the treatment of obesity and eating disorders, diabetes, multiple sclerosis (MS), endometriosis, uterine fibroids,... Agent: Combinent Biomedical Systems, Inc.

20140094409 - Antagonist for (pro)renin receptor for the treatment of hypertension and diabetes: Brain prorenin and the (pro)renin receptor (PRR) have a functional role in the development of hypertension. The present disclosure presents functional PRR antagonistic peptides (e.g., PR10, PR20, PR30, and PR40). In addition, modified peptides comprising one or more thioether-bridges that are stable and strong PRR antagonists are also provided. Methods... Agent:

20140094408 - Medicament for treatment of non-insulin dependent diabetes mellitus, hypertension and/or metabolic syndrome: A dietary supplement or medicament comprising a substance including the chemical structure of bicyclo [3.2.1]octan or the chemical structure of kaurene. The medicament is useful for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome. The possible substances include steviol, isosteviol or stevioside.... Agent:

20140094410 - Silk fibroin materials and use thereof: The present invention provides processes for producing porous silk fibroin scaffold material. The porous silk fibroin scaffold can be used for tissue engineering. The porosity of the silk fibroin scaffolds described herein can be adjusted as to mimic the gradient of densities found in natural tissue. Accordingly, methods for engineering... Agent:

20140094411 - Method of purifying proteins: The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.... Agent: Csl Behring LLC

20140094412 - Selective alfavbeta3 receptor peptide antagonist for therapeutic and diagnostic applications: The present invention is related to new peptide antagonists of αvβ3 receptor, designed on the basis of the crystal structure of integrin αvβ3 in complex with c(RGDf[NMe]V) and the NMR structure of echistatin. These peptides are potent and selective antagonists of the αvβ3 receptor and can be used as novel... Agent: Advanced Accelerator Applications

20140094413 - Hepatocyte growth factor (hgf) mimics as therapeutic agents: Small molecule, peptidic hepatocyte growth factors mimics, which act as both mimetics and antagonists, have been generated. These molecules have been shown or predicted to have therapeutic potential for numerous pathologies including dementia, Alzheimer's disease, Parkinson's disease, amyotrphic lateral sclerosis, and other neurodegenerative diseases, spinal cord injury, traumatic brain injury,... Agent: Washington State University

20140094414 - Composition for preventing or treating neurodegenerative disease including bioactive peptide as effective component: There is provided a new use of protein hydrolysates and peptide derived from seahorses for preventing or treating a neurodegenerative disease, and more particularly a composition and health functional foods for preventing or treating a neurodegenerative disease including seahorse protein hydrolysates or peptide isolated and purified from the same as... Agent: Pukyong National University Industry-university Cooperation Foundation

20140094415 - High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain: The invention provides novel potent inhibitors of the ternary protein complex of nNOS, PSD-95, and the NMDA receptor and pharmaceutical compositions comprising the inhibitors for prophylaxis and/or treatment of excitotoxic-related disease and chronic pain conditions in a subject. The inhibitors are dimeric PSD-95 inhibitors comprising a first peptide or peptide... Agent:

20140094417 - Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of... Agent: The United States Of America,as Represented By The Secretary, Department Of Health And Human Servic

20140094416 - Sparc angiogenic domain and methods of use: The invention provides compositions and methods which exploit the discovery of the SPARC carboxy angiogenic domain.... Agent: Abraxis Bioscience, LLC

20140094418 - Palatable ductile chewable veterinary composition: The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and/or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like... Agent: Novartis Ag

20140094419 - Injectable aqueous ophthalmic composition and method of use therefor: The present invention is directed to the provision of an ophthalmic composition suitable for intravitreal injection. The composition includes an amount of complexing agent that reacts with one or more endogenous components (e.g., hyaluronic acid) in the eye to form a mass of enhanced viscosity. This mass can aid in... Agent: Alcon Research Ltd.

20140094420 - Hydrogel-forming material: where R1 is a C9-23 aliphatic group; R2 is a hydrogen atom or a C1-4 alkyl group which optionally has a C1-2 branched chain; R3 is a —(CH2)n—X group; n is a number from 1 to 4; and X is an amino group, a guanidino group, a —CONH2 group, or... Agent: Nissan Chemical Industries, Ltd.

20140094421 - Herbal medicinal composition for treatment of women infertility and a method of preparing the same: The embodiments herein provide a herbal medicinal composition for effectively treating a women infertility and a method for preparing the same. The composition comprises elm tree wood, a camel fat and water. The composition is prepared by taking several pieces of elm tree wood in a container and adding camel... Agent:

20140094422 - Triazole compounds and methods of making and using the same: e

20140094423 - Aqueous hair cleansing agent: An aqueous hair cleansing agent contains a sulfate-type anionic surfactant having a specific structure, an ether carboxylate-type anionic surfactant having a specific structure, and an organic carboxylic acid or salt thereof, thereby has a pH of 1 to 5 at 25° C. when diluted 20-fold with water.... Agent: Kao Corporation

20140094424 - Microbicidal compositions and methods of production use thereof: Microbicidal compositions that exhibit enhanced microbial efficacy are disclosed, as well as methods of producing and using the microbicidal compositions.... Agent: Siemens Healthcare Diagnostics Inc.

20140094500 - Multiple exon skipping compositions for dmd: Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.... Agent: Sarepta Therapeutics, Inc.

20140094503 - Rna interference mediated inhibition of isocitrate dehydrogenase (idh1) gene expression: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of IDH1 and mutant IDH1 gene expression and/or activity, and/or modulate an IDH1 or mutant IDH1 gene expression pathway. Specifically, the invention relates to double-stranded... Agent:

20140094502 - Rnai inhibition of ctgf for treatment of ocular disorders: RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.... Agent: Novartis Ag

20140094501 - Sirna sequence-independent modification formats for reducing off-target phenotypic effects in rnai, and stabilized forms thereof: Modification formats having modified nucleotides are provided for siRNA. Short interfering RNA having modification formats and modified nucleotides provided herein reduce off-target effects in RNA interference of endogenous genes. Further modification formatted siRNAs are demonstrated to be stabilized to nuclease-rich environments. Unexpectedly, increasing or maintaining strand bias, while necessary to... Agent: Applied Biosystems, LLC

20140094505 - Biomarkers for assessing treatment of sialic acid deficiency diseases and conditions: The present invention relates to methods of monitoring and assessing sialic acid deficiency treatment as well as to methods of predicting/determining responsiveness to treatment for a sialic acid deficiency using biomarkers. Sialic acid deficiencies include for example Hereditary Inclusion Body Myopathy (HIBM).... Agent: Ultragenyx Pharmaceutical Inc.

20140094504 - Human toll-like receptor inhibitors and methods of use thereof: Provided herein are human Toll-like receptor (TLR)-inhibitors and methods for use in individuals having an autoimmune disease or an inflammatory disorder. The TLR inhibitors of the present disclosure are polynucleotides comprising an inhibitory motif for one or more of TLR7, TLR8 and TLR9.... Agent: Dynavax Technologies Corporation

20140094506 - Use of light sensitive genes: The invention relates to the use of a light-gated ion channel for the manufacture of a medicament for the treatment of blindness and a method for expressing said cell specific fashion, e.g. in ON-bipolar cells, ON-ganglion cells, or AII amacrine cells.... Agent: Novartis Forschungsstiftung

20140094425 - Methods for transdifferentiation of body tissues: The invention relates to methods for transdifferentiation of body tissues which can be used to generate specific cell types needed for regenerating organs or body parts, following cellular degeneration, injury or amputation. The present invention also describes the use of tissue transdifferentiation for treating cancer and autoimmune diseases.... Agent:

20140094426 - Amphiphile prodrugs: Amphiphilic prodrugs of general formula A-X are disclosed, wherein A is a biologically active agent or may be metabolized to a biologically active agent; and X is R, or up to three R moieties attached to a linker, Y1, Y2 or Y3. Self-assembly of the amphiphilic prodrugs into reverse lyotropic... Agent:

20140094428 - Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia: A first aspect of the invention relates to a method of treating AML in a subject, said method comprising administering to a subject a therapeutically effective amount of (i) sapacitabine, or a metabolite thereof; and (ii) decitabine; in accordance with a dosing regimen comprising at least one first treatment cycle... Agent:

20140094427 - Dosing methods for treating disease: f

20140094429 - Fgf receptor-activating 3-o-alkyl oligosaccharides, preparation thereof and therapeutic use thereof:

20140094430 - Hyaluronic acid compositions stabilised against the degrading effect of heat or enzymes: The invention relates to the use of an additive to stabilise hyaluronic acid formulated in an aqueous composition against the degrading effect of heat or of enzymes such as hyaluronidase, characterised in that said additive comprises one or more polysaccharides having a molecular weight equal to or greater than 20,000... Agent: Altergon S.a.

20140094431 - Methods of making hydrogels for soft tissue augmentation: Hair-like shaped crosslinked hydrogels and methods for preparing such crosslinked hydrogels and are provided.... Agent: Allergan, Inc.

20140094434 - Amino acid composition: Amino acid compositions containing a carbohydrate and any one or more kinds of alanine, proline and glycine as amino acid can suppress a rapid increase in the blood glucose level immediately after ingestion and a decrease in the blood glucose level due to prolonged exercise, and can improve exercise performance.... Agent: Ajinomoto Co., Inc.

20140094433 - Dermal filler hydrogels with vitamin a/cyclodextrin inclusion complexes: Compositions, such as hydrogel compositions, that include a hyaluronic acid, a vitamin A, and a cyclodextrin may be used as medical or cosmetic fillers, implants, or creams. For example, the compositions may be used as dermal fillers.... Agent: Allergan, Inc.

20140094432 - Methods and systems for polymer precipitation and generation of particles: Processes for precipitating polymers from a polymer-containing solution are disclosed.... Agent: Cerulean Pharma Inc.

20140094435 - Use of dextran sulfate: A method of inhibiting Instant Blood-Mediated Inflammatory Reaction (IBMIR) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate,... Agent: Tx Medic Ab

20140094436 - Imidazole compounds that modulate hsp90 activity: Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in... Agent: Synta Pharmaceuticals Corp.

20140094437 - High alcohol content foaming compositions: This invention relates to a “high lower alcohol content”(>40% v/v of a C1-4 alcohol) liquid composition able to be either dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers or as an alcohol gel composition which does not use thickener and gelling agents... Agent: Deb Worldwide Healthcare Inc.

20140094438 - Compositions and methods for the treatment of pain: The claimed invention relates to compositions that may be in a form of a liquid, solid, gel, cream or gel capsule comprising an analgesic, and methods for administering these compositions for treatment of patients suffering from various forms of pain.... Agent: Gm Pharmaceuticals, Inc.

20140094439 - Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable... Agent:

20140094440 - Natural combination hormone replacement formulations and therapies: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with... Agent: Therapeuticsmd, Inc.

20140094441 - Natural combination hormone replacement formulations and therapies: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with... Agent: Therapeuticsmd, Inc.

20140094442 - Combinations comprising anti-muscarinic agents and corticosteroids: Combinations comprising (a) a corticosteroid and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for treatment of respiratory disease, e.g., asthma or chronic... Agent:

20140094443 - Tgr5 modulators and methods of use thereof: m

20140094444 - Compositions and methods for tissue engineering and cell based therapies: The present application discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, S1P1/S1P3 activation with FTY720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (EPCs) with the potential to increase... Agent: University Of Virginia Patent Foundation

20140094446 - Cyclic amino acids for the treatment of pain: Compositions comprising cyclic amino acids or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier. Said compositions are for use in the treatment of pain. Pain includes both acute and chronic forms of pain. The preferred cyclic amino acid is 1-aminocyclobutane-1-carboxylic acid (ACBC).... Agent: Therexcell Pharma Inc.

20140094445 - Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors: In one aspect, the invention relates to substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with... Agent: University Of Utah Research Foundation

20140094447 - Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor: Pharmaceutical compositions and methods for treating or preventing bacterial infections are disclosed. The pharmaceutical compositions typically comprise pharmaceutically effective amount of: (a) sulbactam or a pharmaceutically acceptable salt thereof, and (b) at least one beta-lactamase inhibitor or a pharmaceutically acceptable salt thereof, with the provision that the beta-lactamase inhibitor is... Agent:

20140094448 - Pyrazolopyrimidines and related heterocycles as ck2 inhibitors: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and have the following general formula:... Agent: Senhwa Biosciences, Inc.

20140094449 - Treatment of bipolar disorder: The invention relates to sulphur- and/or selenium-containing compounds that can inhibit the enzyme inositol mono-phosphatase (IMPase), and which can be used in treating conditions that are treatable through inhibition of this enzyme, such as bi-polar disorder, the compounds having a structure of Formula (I), or is a pharmaceutically acceptable salt... Agent: Isis Innovation Ltd.

20140094450 - Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators: in which R′, R″, R′″, R1, R2, R3, R4, R5, R6 and Z are defined as indicated below. The compounds of the formula I are APJ receptor modulators, and are useful for the treatment of diseases associated with increased blood pressure for example. The invention furthermore relates to the use... Agent: Sanofi

20140094451 - Preventive or remedy for glaucoma: There is provided a preventive for glaucoma or a preventive or a remedy for ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. A preventive or a remedy for glaucoma comprising a Rho kinase inhibitor and an α1 blocker in combination.... Agent: Kowa Co., Ltd.

20140094452 - Rapid onset liquid midazolam composition for buccal administration: This application discloses liquid compositions for administration to a patient comprising midazolam and a pharmaceutically acceptable carrier, wherein the pH of the composition is about 6 or higher, the composition comprises less than about 200 mg/ml cyclodextrin, and at least about 50% of the midazolam is present in solution. Uses... Agent: Special Products, Ltd.

20140094453 - Sweet flavor modifier: The present invention includes compounds having structural formula (I), or salts or solvates thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of modulating the sweet taste of compositions.... Agent:

20140094454 - Tetrahydropyrrolothiazine compounds: e

20140094455 - Aquaporin modulators and methods of using them for the treatment of edema and fluid imbalance: Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins.... Agent: Arizona Board Of Reagents On Behalf Of The University Of Arizona

20140094456 - Anti-fibrotic pyridinones: Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.... Agent:

20140094458 - Cyclic progestin regimens and kits: A method of contraception is provided which involves delivery of 21 to 27 consecutive days of a progestin in the absence of an estrogen or other steroidal compound, followed by 1 to 7 days without an effective amount of an active agent. Also described is a pharmaceutically useful kit to... Agent: Wyeth LLC

20140094457 - Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated rna decay: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature termination codons, or other conditions that render messenger ribonucleic acid (mRNA) susceptible to nonsense mediated RNA decay, in... Agent: New York University

20140094459 - Tyrosine kinase inhibitors: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as... Agent: Princpia Biopharma Inc.

20140094460 - Fused heterocyclic compounds as ion channel modulators: e

20140094461 - Biomarkers for hedgehog inhibitor therapy: A method of selecting a subject having cancer for treatment with a Hedgehog signaling inhibitor by determining the level of expression of at least one biomarker in a biological sample derived from the subject.... Agent:

20140094463 - Pharmaceutical compositions: The present invention relates to carrier systems useful for pharmaceutical compositions. These carriers comprise an emulsifier, and also in further embodiments a polymeric dissolution aid. These carriers are useful for delivering pharmaceutical actives such as antimicrobial agents.... Agent: Rib-x Pharmaceuticals, Inc.

20140094462 - Sonic hedgehog modulators: Sonic Hedgehog modulators and methods of use thereof are provided for.... Agent:

20140094464 - Quinone compounds for treating ape1 mediated diseases: The invention described herein pertains to compounds and compositions for treating Ape1 mediated diseases. In particular, the invention described herein pertains to quinone compounds and pharmaceutical compositions containing them for treating Ape1 mediated diseases.... Agent: Indiana University Research And Technology Corporation

20140094465 - Compounds as s-nitrosoglutathione reductase inhibitors: The present invention is directed to compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.... Agent:

20140094466 - Ssh-2 (slingshot-2) inhibitors and methods for making and using them: In alternative embodiments, the invention provides compositions that inhibit the polypeptide SSH-2, or SlingSHot-2, a phosphatase enzyme that regulates actin filaments, and methods for making and using them, including methods comprising administering compositions of the invention to regulate or modify actin filament polymerization by inhibiting SSH-2, where in one embodiment... Agent:

20140094470 - Combination treatment for dermatological conditions: The invention relates to a method of treating dermatological conditions or symptoms associated therewith in a patient in need thereof by topically administering an effective amount of a combination of brimonidine or a pharmaceutically acceptable salt thereof and oxymetazoline or a pharmaceutically acceptable salt thereof to the affected area of... Agent: Galderma Laboratories Inc.

20140094467 - Method and composition for modulating canonical wnt pathway using folate and inositol: The canonical Wnt signaling pathway is implicated in many disorders including neural tube defects, limb malformations, and heart defects, developmental disorders associated with alcohol exposure (fetal alcohol syndrome) or exposure to bipolar medications (i.e. lithium), wound healing, and Alzheimer's disease. Elevated plasma homocysteine (HCy), which results from folate (folic acid,... Agent: University Of South Florida

20140094469 - Methods and compositions for safe and effective treatment of erythema: Improved methods and compositions for safe and effective treatment of erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical composition comprising about 0.3% to about 10% by weight of brimonidine and a pharmaceutically acceptable carrier.... Agent: Galderma Research & Development

20140094468 - Pteridines useful as hcv inhibitors and methods for the preparation thereof: The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes... Agent: Tibotec Pharmaceuticals Ltd.

20140094471 - Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.... Agent: Genentech, Inc.

20140094472 - Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives: The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is... Agent: Alkermes Pharma Ireland Limited

20140094473 - Inhibitors of influenza viruses replication: or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (I) are as described herein. A pharmaceutical composition comprises an effective amount of... Agent: Vertex Pharmaceuticals Incorporated

20140094474 - Androgen receptor modulating carboxamides: wherein Rx, Rz, R9, R10, R14, R14′, R15, R15′, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other... Agent: Orion Corporation

20140094475 - Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof: Disclosed are solid forms of antiretroviral compounds and anti-oxidative acids, and processes for their preparation. Pharmaceutical compositions using the solid forms are also disclosed.... Agent: Laurus Labs Private Limited

20140094476 - Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile: The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent:

20140094477 - Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile: The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent:

20140094478 - Composition and tablet comprising raltegravir: The present invention relates to a composition and tablet comprising raltegravir and to a process for the preparation of such tablet.... Agent: Ratiopharm Gmbh

20140094479 - Process for producing a solid dispersion of an active ingredient: A process for producing a solid dispersion of an active ingredient which comprises feeding the active ingredient and a matrix-forming agent to an extruder and forming a uniform extrudate, wherein the extruder comprises at least two rotating shafts (2), each of the shafts (2) carrying a plurality of processing elements... Agent: Abbvie Deutschland Gmbh & Co. Kg

20140094480 - Pro-neurogenic compounds: This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protection from neuron cell death.... Agent: Board Of Regents Of The University Of Texas System

20140094482 - Benzazocine-ring compound inhibition of tau hyperphosphorylation: A method of inhibiting hyperphosphorylation of the tau protein and/or a TLR4-mediated immune response is disclosed. The method contemplates administering to cells in recognized need thereof such as cells of the central nervous system a FLNA-binding effective amount of a FLNA-binding benzazocine-ring compound or a pharmaceutically acceptable salt thereof such... Agent:

20140094481 - Tamper resistant dosage forms: Tamper resistant controlled release formulations.... Agent: Euro-celtique S.a.

20140094483 - Novel iso-ergoline derivatives: Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors... Agent: Map Pharmaceuticals, Inc.

20140094485 - Solid state forms of hiv inhibitor: The invention relates to a novel hemi-succinate salt form of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid and a novel crystalline form thereof, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the treatment of Human Immunodeficiency Virus (HIV) infection.... Agent:

20140094486 - Solid state forms of hiv inhibitor: The invention relates to novel crystalline forms of (2S)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid, the hydrochloride salt thereof, novel crystalline forms of the hydrochloride salt, methods for the preparation thereof, pharmaceutical compositions thereof and their use in the treatment of Human Immunodeficiency Virus (HIV) infection.... Agent:

20140094484 - Sustained delivery formulations of rapamycin compounds: The present invention relates to a rapamycin sustained release delivery system for treatment of diseases responsive to rapamycin. The sustained release delivery system of the invention includes a flowable composition containing rapamycin or a rapamycin derivative, which is capable of providing an implant containing the rapamycin or derivative thereof. The... Agent: Tolmar Therapeutics, Inc.

20140094487 - Dihydro-6-azaphenalene derivatives for the treatment of cns, oncological diseases and related disorders: In one embodiment, the present application discloses 2-aza-, 2-oxa- and 2-thia-2,3-dihydro-6-azaphenalene compounds and compositions, and methods for treating a neurological disease in a patient in need thereof using the compounds and compositions as disclosed herein.... Agent: Warner Babcock Institute For Green Chemistry, LLC

20140094488 - 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors: The invention relates to the compounds of general formula (I): Preparation process and therapeutic use.... Agent: Sanofi

20140094489 - Heterocyclic carboxylic acid ester derivative: e

20140094490 - Anti-neurodegenerative disease agent: wherein in General formula 1, R1 through R3 independently represent a hydrogen atom or an appropriate substituent; Z1 represents a heterocyclic ring and Z2 represents the same or different heterocyclic or aromatic ring as in Z1, wherein the heterocyclic and aromatic rings optionally have a substituent; o represents an integer... Agent: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo

20140094491 - Dimethyl-benzoic acid compounds: e

20140094492 - Derivatives of sulindac, use thereof and preparation thereof: Derivatives of sulindac that lack cyclooxygenase inhibitory activity are provided along with pharmaceutical compositions containing them and use for treatment or prevention of cancer. The derivatives of sulindac are also suitable for treating chronic inflammatory conditions. A method for preparing the derivatives is also provided.... Agent: Southern Research Institute

20140094493 - Novel ether linked compounds and improved treatments for cardiac and cardiovascular disease: r

20140094494 - Antifungal treatment: A method of treating or preventing fungal infection, which includes identifying a plant or animal having a fungal infection and administering an effective amount of an anti-fungal composition to the plant or animal to reduce the fungal infection. In a preferred form of the present invention, the antifungal composition is... Agent: Wisconsin Alumni Research Foundation

20140094495 - Antimicrobial haloalkyl heterocycle compounds: This application describes compounds useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents.... Agent: Novabay Pharmaceuticals, Inc.

20140094496 - Formulations of bendamustine: Methods of treatment using bendamustine formulations designed for small volume intravenous administration are disclosed. The methods conveniently allow shorter administration time without the active ingredient coming out of solution as compared to presently available formulations.... Agent: Eagle Pharmaceuticals, Inc.

20140094497 - Angiotensin in treating brain conditions: The present invention provides, among other things, methods and compositions for treating brain conditions. In some embodiments, the methods include administering to a subject suffering from or susceptible to a brain condition an angiotensin (1-7) peptide via either an intravenous or subcutaneous route of administration.... Agent:

20140094498 - Methods and compositions for treating post-operative pain comprising clonidine: The present invention is directed to an implantable drug depot useful for reducing, preventing or treating post-operative pain in a patient in need of such treatment, the implantable drug depot comprising a therapeutically effective amount of clonidine or pharmaceutically acceptable salt thereof and a polymer; wherein the depot is implantable... Agent: Warsaw Orthopedic, Inc.

20140094499 - Formulations of (r)-1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl)cyclopropanecarboxamide: The present invention relates to formulations of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), pharmaceutical packs or kits thereof, and methods of treatment therewith.... Agent: Vertex Pharmaceuticals Incorporated

20140094507 - Modulators of tlr3/dsrna complex and uses thereof: e

20140094508 - Compositions and methods of inhibiting n-acylethanolamine-hydrolyzing acid amidase: Compounds and pharmaceutical compositions are contemplated that inhibit N-acyl-ethanolamine-hydrolyzing acid amidase (NAAA) to so increase the concentration of the substrate of NAAA, palmitoylethanolamide (PEA). NAAA inhibition is contemplated to be effective to alleviate conditions associated with a reduced concentration of PEA. Among other uses, various NAAA inhibitors are especially contemplated... Agent: Universita Degli Studi Di Urbino "carlo Bo"

20140094509 - Non-aqueous taxane nanodispersion formulations and methods of using the same: Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is... Agent: Teikoku Pharma Usa, Inc.

20140094510 - Non-aqueous taxane nanodispersion formulations and methods of using the same: Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is... Agent: Teikoku Pharma Usa, Inc.

20140094511 - Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent: This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil,... Agent: Vivus, Inc.

20140094513 - Composition and method for neuroprotection against excitotoxic injury: The present invention discloses the combined treatment of memantine (N-methyl-D-aspartate receptor antagonist) and tea polyphenol (an antioxidant and anti-inflammatory agent) is more effective (synergistic) in neuroprotection than either memantine or tea polyphenol alone in mouse excitotoxic injury. These findings provide useful information about the potential application of memantine and tea... Agent: National Taiwan Unversity

20140094512 - Method of modulating the degree of adipose tissue deposited intramuscularly: The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in cattle by administration of a retinoic receptor antagonist or inverse agonist and compounds for use in such method.... Agent:

20140094514 - Pharmaceutical and food compositions for preventing or treating diabetes or obesity: The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of... Agent: Korea Ocean Research And Development Institute

20140094515 - Cosmetic particles that transform from hard to soft particles comprising hydrogenated long-chain triglyceride oils: Cosmetic particle compositions are provided which are adapted to form hard cosmetic particles that transform to soft cosmetic particles after their incorporation into topical formulations, particularly surfactant-based topical formulations. The composition includes one or more partially or fully hydrogenated triglyceride oils, at least 50% of which have at least 15%... Agent: International Flora Technologies, Ltd.

20140094516 - Method of utilizing azelaic acid esters to modulate communications mediated by biological molecules: The treatment of disease in organisms using Macromolecular interaction modulators and Membrane active immunomodulators, particularly selected azelaic acid esters, individually and in combinations, to modulate communications between biological molecules.... Agent:

20140094517 - Preservative system for cosmetic formulations- compositions and methods thereof: The present invention relates to preservation of cosmetic formulations. More specifically, the present invention relates to a preservative composition for cosmetic formulations comprising thymol, monolaurin and magnolol obtained from supercritical fluid extracts of Magnolia officinalis.... Agent:

20140094518 - Method for regulating retinal endothelial cell viability: Here provided is a method for regulating retinal endothelial cell viability in a mammal by administering to the mammal a therapeutically effective amount of a quinic acid analog. The method may be applied to prevent, treat or cure pathological conditions of retinal endothelial cells associated with radiation retinopathy, diabetic retinopathy... Agent: The University Of Tennessee Research Foundation

20140094519 - Lipoxin analogs as novel inhibitors of angiogenesis: The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (PUFA) such as arachidonic acid (AA), oxygenases and the analgesic aspirin (ASA). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate... Agent:

20140094520 - Omega-3 pentaenoic acid compositions and methods of use: Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA)... Agent: Matinas Biopharma, Inc.

20140094521 - Benzylamine derivative: The objective of the present invention is to provide a new compound which is effective in treating blood cancer, particularly multiple myeloma, and which is also effective in suppressing an SP cell, i.e. Side Population Cell, which is a cause of recurrence of cancer. The compound according to the present... Agent: The University Of Tokushima

20140094522 - Compound formulations of 2-amino-1, 3-propanediol compounds: Pharmaceutical concentrate formulations comprising 2-amino-1,3-propanediol compounds, analogs thereof and salts thereof, particularly 2-amino-2-[2-(4-octylphenyl)ethyl]-propane-1,3-diol or a pharmaceutically acceptable salt thereof in an organic solvent or semi-aqueous solvent and methods for administration of the undiluted and diluted concentrate are provided.... Agent: Novartis Ag

20140094523 - Solid ambroxol-containing preparation: The present invention relates to solid preparations containing ambroxol which are obtainable by melt extrusion of the mixture consisting of a) 30 to 80% by weight of ambroxol hydrochloride, b) 2 to 68% by weight of at least one hydrogenated vegetable oil, c) 2 to 68% by weight of at... Agent: Boehringer Ingelheim International Gmbh

20140094524 - Astaxanthin-containing pet foods: There is provided pet food comprising astaxanthin and/or an ester thereof as an active component and having an effect of deodorizing excrement such as urine and feces, effects of improving sleep, sensibility such as perception and cognition, and visual sense, and an effect of treating, improving or preventing diabetes and... Agent:

20140094525 - Foamable alcoholic composition: A foamable composition is provided that includes at least 40 weight percent alcohol, based upon the total weight of the alcoholic composition; and a foaming surfactant selected from the group consisting of silicone quats.... Agent: Gojo Industries, Inc.

20140094527 - Method for extracting an odorous extract by an alternative solvent to conventional solvents: Methods for extracting an extract of volatile odorous compounds from an organic raw material containing odorous compounds is disclosed. The method includes contacting an organic raw material with dimethyl carbonate, as a solvent, in at least one bath at a temperature of 10° C. to 70° C. A liquid organic... Agent: Charabot

20140094526 - Ph dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable... Agent: Plx Pharma Inc.

20140094528 - Oil-based gel-like composition: Provided is a gel-forming agent that is easy to prepare and has all the properties including high safety for the living body and the environment, satisfactory gel-forming capability, comfortable feeling upon use, and good handleability. The gel-forming agent includes a lecithin, and a polyglycerol fatty acid ester in an amount... Agent: Daicel Corporation

20140094529 - Molecular containers and methods of making and using same: Acyclic CB[n]-type compounds, methods of making such compounds, and uses of the compounds. For example, these compounds can be used as nanocontainers to solubilize pharmaceutical agents. Also provided are compositions and methods of using them for therapy or prophylaxis of a wide variety of conditions for which therapy or prophylaxis... Agent: University Of Maryland, College Park

  
  
Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140410: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 1.48554 seconds

PATENT INFO